Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsRDPTF 3-Year ROIIC % is 153.02 as of Jun. 2025, which is at its 10-year median of 153.02. The stock has 5 warning signs investors should review. Among 1,320 Biotechnology companies, Radiopharm Theranostics ranks better than 82.2% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Radiopharm Theranostics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 153.02%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Radiopharm Theranostics's 3-Year ROIIC % or its related term are showing as below:
RDPTF's 3-Year ROIIC % is ranked better than 82.2% of 1320
companies
in the Biotechnology industry
Industry Median: -4.835
vs RDPTF: 153.02
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Radiopharm Theranostics 3-Year ROIIC % Related Terms
Radiopharm Theranostics 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDPTF vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's 3-Year ROIIC % falls into.
Radiopharm Theranostics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -22.553 (Jun. 2025) - -13.996 (Jun. 2022) )
/
( 33.997 (Jun. 2025) - 43.459 (Jun. 2022) )
=
-8.557
/
-9.462
=
90.44%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Radiopharm Theranostics (RDPTF) has a 3-Year ROIIC % of 153.02 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Radiopharm Theranostics and its competitors. This is near median its historical median of 153.02. Over the past decade, Radiopharm Theranostics' 3-Year ROIIC % has ranged from 153.02 to 153.02. According to the industry distribution chart, Radiopharm Theranostics ranks #235 out of 1320 companies in the Biotechnology industry, placing it in the top 17.8%.
Is Radiopharm Theranostics' 3-Year ROIIC % too high?
Radiopharm Theranostics' current 3-Year ROIIC % of 153.02 is near median its 10-year median of 153.02. Over the past 10 years, this metric has ranged from a low of 153.02 to a high of 153.02. Based on the distribution chart, Radiopharm Theranostics ranks #235 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Radiopharm Theranostics' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #235 out of 1320 companies for 3-Year ROIIC %. This places Radiopharm Theranostics in the top 18% of its industry — outperforming the majority of peers. Historically, Radiopharm Theranostics' own 3-Year ROIIC % has ranged from 153.02 to 153.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current 3-Year ROIIC % is 153.02, which is near median its own 10-year median of 153.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (RDPTF) has a current 3-Year ROIIC % of 153.02. The current 3-Year ROIIC % is 153.02, which is near median its 10-year median of 153.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Radiopharm Theranostics (RDPTF), the current 3-Year ROIIC % is 153.02 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDPTF has been successfully added to your 
